ClinicalTrials.gg
TerminatedNCT06365437Updated Mar 12, 2026Results posted

A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation

A Phase 2 interventional study of TCD601 and Tacrolimus (TAC) in Kidney Transplantation, sponsored by ITB-Med LLC. Terminated at 7 sites in 3 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-03-12.

Sponsored by ITB-Med LLC · Phase 2, Interventional, and Basic science

Why this study was terminated
After enrolment was complete, and sufficient data was collected to fully characterize the highest dose cohort, study follow up was terminated by the sponsor for non-safety related reasons.

From the registry’s dates

  • Registered 2 years 10 months after the study started (first participant enrolled Jun 2021, registered Apr 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The purpose of this study is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of escalating doses of TCD601 when compared to rATG in de novo renal transplant patients.

02

Conditions studied

  • Kidney Transplantation
03

In context

Lead sponsor

ITB-Med LLC is the lead sponsor of 9 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to understand the study requirements and provide written before and study assessment is performed.
  • Male or female patients ≥ 18 to 70 years of age.
  • Recipients of a de novo renal allograft from a heart-beating deceased, living unrelated, or non-HLA identical living related donor.
  • Recipients of a kidney with a cold ischemia time (CIT) less than 30 hours.

Exclusion criteria

Exclusion Criteria:

  • Multiple-organ transplant recipients
  • Subjects who have received a kidney allograft previously
  • Recipient of a kidney from an HLA identical living related donor
  • Recipient of a kidney from a donor after cardiac death
  • Subjects at high immunological risk for rejection
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Arm 1

    TCD601 0.2 mg/kg administered with the contemporary standard of care (SoC) consisting of concentration-controlled tacrolimus (TAC) combined with mycophenolate mofetil (MMF) and corticosteroids (CS).

    Biological: TCD601 · Drug: Tacrolimus (TAC) · Drug: Corticosteroids (CS) · Drug: Mycophenolate Mofetil (MMF)

  • Experimental
    Arm 2

    TCD601 0.6 mg/kg administered with the contemporary standard of care (SoC) consisting of concentration-controlled tacrolimus (TAC) combined with mycophenolate mofetil (MMF) and corticosteroids (CS).

    Biological: TCD601 · Drug: Tacrolimus (TAC) · Drug: Corticosteroids (CS) · Drug: Mycophenolate Mofetil (MMF)

  • Experimental
    Arm 3

    TCD601 1.7 mg/kg administered with the contemporary standard of care (SoC) consisting of concentration-controlled tacrolimus (TAC) combined with mycophenolate mofetil (MMF) and corticosteroids (CS).

    Biological: TCD601 · Drug: Tacrolimus (TAC) · Drug: Corticosteroids (CS) · Drug: Mycophenolate Mofetil (MMF)

  • Experimental
    Arm 4

    TCD601 5.0 mg/kg administered with the contemporary standard of care (SoC) consisting of concentration-controlled tacrolimus (TAC) combined with mycophenolate mofetil (MMF) and corticosteroids (CS).

    Biological: TCD601 · Drug: Tacrolimus (TAC) · Drug: Corticosteroids (CS) · Drug: Mycophenolate Mofetil (MMF)

  • Active comparator
    Arm 5

    ATG 1.5 mg/kg administered with the contemporary standard of care (SoC) consisting of concentration-controlled tacrolimus (TAC) combined with mycophenolate mofetil (MMF) and corticosteroids (CS).

    Drug: Tacrolimus (TAC) · Drug: Corticosteroids (CS) · Drug: Mycophenolate Mofetil (MMF) · Drug: ATG

Interventions

  • BiologicalTCD601

    Investigational Product

    Also known as: Siplizumab

  • Standard of Care Concomitant Immunosuppression

  • DrugCorticosteroids (CS)

    Standard of Care Concomitant Immunosuppression

  • Standard of Care Concomitant Immunosuppression

  • DrugATG

    Standard of Care induction therapy in solid organ transplantation

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v5.0.

    Time frame: 12 months

  2. Measure Peak TCD601 Plasma Concentration (Cmax) Over Time.

    The maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after single dose administration.

    Time frame: 12 months

  3. Measure the Area Under the TCD601 Plasma Concentration Versus Time Curve (AUC).

    The AUC from time zero to the last measurable concentration sampling time.

    Time frame: 12 months

Secondary outcomes

  1. The Incidence of Allograft Rejection at 12 Months Post-Transplant

    Time frame: 12 months

  2. To Assess Renal Function Over Time

    Time frame: 12 months

07

Results

Posted Mar 12, 2026

Participant flow

Participant flow — Overall Study
MilestoneArm 1Arm 2Arm 3Arm 4Arm 5
Started65885
Completed54703
Not completed11182

Outcome measures

PrimaryNumber of Participants With Treatment-related Adverse Events as Assessed by CTCAE v5.0.
Time frame:
12 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v5.0.
ParticipantsArm 1Arm 2Arm 3Arm 4Arm 5
At least 1 TEAE — Yes65885
At least 1 TEAE — No00000
At least 1 TEAE Related to Study Medicatoin — Yes64885
At least 1 TEAE Related to Study Medicatoin — No01000
At least 1 SAE — Yes31440
At least 1 SAE — No34445
At least 1 TEAE leading to Study Discontinuation — Yes00110
At least 1 TEAE leading to Study Discontinuation — No65775
At least 1 TEAE leading to Dose adjustment — Yes00000
At least 1 TEAE leading to Dose adjustment — No65885
At least 1 TEAE leading to Dose interruption — Yes00010
At least 1 TEAE leading to Dose interruption — No65875
At least 1 TEAE leading to Study Medication Discontinuation — Yes00120
At least 1 TEAE leading to Study Medication Discontinuation — No65765
At least 1 Infection — Yes62822
At least 1 Infection — No03063
At least 1 Serious Infection — Yes00100
At least 1 Serious Infection — No65785
At least 1 SAE related to Study Medication — Yes00230
At least 1 SAE related to Study Medication — No65655
PrimaryMeasure Peak TCD601 Plasma Concentration (Cmax) Over Time.

The maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after single dose administration.

Time frame:
12 months
Reported as:
Mean · ug/mL
Measure Peak TCD601 Plasma Concentration (Cmax) Over Time.
ug/mLArm 1Arm 2Arm 3Arm 4
Measure Peak TCD601 Plasma Concentration (Cmax) Over Time.4.3 ± 0.57812.8 ± 1.9650.6 ± 9.79135 ± 11.8
PrimaryMeasure the Area Under the TCD601 Plasma Concentration Versus Time Curve (AUC).

The AUC from time zero to the last measurable concentration sampling time.

Time frame:
12 months
Reported as:
Mean · ug/mLxday
Measure the Area Under the TCD601 Plasma Concentration Versus Time Curve (AUC).
ug/mLxdayArm 1Arm 2Arm 3Arm 4
Measure the Area Under the TCD601 Plasma Concentration Versus Time Curve (AUC).26.2 ± 4.6795.4 ± 29.3627 ± 2491910 ± 389
SecondaryThe Incidence of Allograft Rejection at 12 Months Post-Transplant
Time frame:
12 months
Reported as:
Count of participants · Participants
The Incidence of Allograft Rejection at 12 Months Post-Transplant
ParticipantsArm 1Arm 2Arm 3Arm 4Arm 5
The Incidence of Allograft Rejection at 12 Months Post-Transplant00100
SecondaryTo Assess Renal Function Over Time
Time frame:
12 months
Reported as:
Mean · mL/min/1.73m^2
To Assess Renal Function Over Time
mL/min/1.73m^2Arm 1Arm 2Arm 3Arm 4Arm 5
Baseline32.99 ± 15.67161.8 ± 20.52151.85 ± 12.01159.45 ± 12.67651.17 ± 8.376
Month 340.51 ± 14.33967.11 ± 21.02852.53 ± 9.41657.92 ± 9.41253.48 ± 4.918
Month 637.98 ± 8.23664.75 ± 11.50152.64 ± 8.72754.64 ± 21.59058.93 ± 4.918
Month 1245.15 ± 9.29570.06 ± 16.05156.96 ± 8.411—61.23 ± 9.02

Adverse events

Collected over 12 Months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 10/6 (0%)3/6 (50%)6/6 (100%)
Arm 20/5 (0%)1/5 (20%)5/5 (100%)
Arm 30/8 (0%)4/8 (50%)8/8 (100%)
Arm 40/8 (0%)4/8 (50%)8/8 (100%)
Arm 50/5 (0%)0/5 (0%)5/5 (100%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventArm 1Arm 2Arm 3Arm 4Arm 5
Delayed Graft FunctionInjury, poisoning and procedural complications2/60/50/80/80/5
Duodenal ulcer haemorrhageGastrointestinal disorders0/61/50/80/80/5
New onset Diabetes after transplantationMetabolism and nutrition disorders1/60/50/80/80/5
Focal Segmental GlomerulosclerosisRenal and urinary disorders1/60/50/80/80/5
Renal ImpairmentRenal and urinary disorders1/60/50/80/80/5
LymphoceleVascular disorders1/60/50/80/80/5
PancreatitisGastrointestinal disorders0/60/50/81/80/5
Transplant RejectionImmune system disorders0/60/50/81/80/5
AppendicitisInfections and infestations0/60/51/80/80/5
Pulmonary NocardiosisInfections and infestations0/60/51/80/80/5
Most frequent other events
Showing 10 of 173
Most frequent other events
EventArm 1Arm 2Arm 3Arm 4Arm 5
Polyomavirus viraemiaInfections and infestations4/60/51/81/81/5
HypertensionVascular disorders4/63/54/82/81/5
Cytomegalovirus viraemiaInfections and infestations3/60/55/81/80/5
LeukopeniaBlood and lymphatic system disorders3/61/54/82/82/5
DiarrhoeaGastrointestinal disorders2/60/54/81/82/5
NauseaGastrointestinal disorders3/60/52/80/80/5
Oedema peripheralGeneral disorders3/60/52/80/80/5
BK virus infectionInfections and infestations3/60/51/80/81/5
NasopharyngitisInfections and infestations3/60/53/80/81/5
HyperkalaemiaInvestigations2/60/54/82/82/5

Baseline characteristics

One participant was randomized, but never received Study Drug and was never received any study procedure during their screening period. Baseline characteristics were collected.

Age, Continuous
Age, Continuous(Years)Arm 1Arm 2Arm 3Arm 4Arm 5Total
Mean48.8 ± 7.7652.2 ± 15.3758.1 ± 7.1349.5 ± 12.7148.6 ± 9.2952 ± 10.65
Sex: Female, Male
Sex: Female, Male(Participants)Arm 1Arm 2Arm 3Arm 4Arm 5Total
Female2024210
Male4574323
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm 1Arm 2Arm 3Arm 4Arm 5Total
American Indian or Alaska Native000000
Asian100102
Native Hawaiian or Other Pacific Islander000000
Black or African American011002
White5487529
More than one race000000
Unknown or Not Reported000000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm 1Arm 2Arm 3Arm 4Arm 5Total
Hispanic or Latino002226
Not Hispanic or Latino6566326
Unknown or Not Reported001001
Region of Enrollment
Region of Enrollment(Participants)Arm 1Arm 2Arm 3Arm 4Arm 5Total
Austria4141111
Sweden2435216
Spain002226
Height
Height(cm)Arm 1Arm 2Arm 3Arm 4Arm 5Total
Mean176.33 ± 11.112177.4 ± 7.369172.63 ± 172173.25 ± 8.828172 ± 11.79174.44 ± 9.059
Weight
Weight(Kg)Arm 1Arm 2Arm 3Arm 4Arm 5Total
Mean80.183 ± 19.37281.82 ± 20.14176.725 ± 15.90980.488 ± 10.99982.160 ± 10.91479.959 ± 14.7251
BMI
BMI(kg/m^2)Arm 1Arm 2Arm 3Arm 4Arm 5Total
Mean25.72 ± 5.62726 ± 6.05025.64 ± 4.26226.81 ± 2.91827.26 ± 3.71326.26 ± 4.247

3 further baseline measures are reported on the registry.

08

Study locations

7 sites
  • Innsbruck Medical University
    Innsbruck, A-6020, Austria
  • University of Vienna
    Vienna, 1090, Austria
  • Hospital Clinic de Barcelona
    Barcelona, 08036, Spain
  • Hospital Universitari de Bellvitge
    Barcelona, 08907, Spain
  • Karolinska University Hospital
    Stockholm, Huddinge 14157, Sweden
  • Sahlgrenska University Hospital
    Gothenburg, 41345, Sweden
  • Skåne University Hospital
    Malmö, 20502, Sweden
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2021 to primary completion in Dec 2024, 42 months.

Results were first posted in Mar 2026, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2024
First posted
Apr 15, 2024
StartActual
Jun 6, 2021
Primary completionActual
Dec 11, 2024
CompletionActual
Dec 11, 2024
Results first posted
Mar 12, 2026
Last update
Mar 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06365437
Lead sponsor
ITB-Med LLC
Responsible party
Sponsor
First posted
Apr 15, 2024
Start date
Jun 6, 2021
Primary completion
Dec 11, 2024
Completion
Dec 11, 2024
Results posted
Mar 12, 2026
Last update
Mar 12, 2026

Study contacts

Fredrik Juhlin
study director · ITB-Med LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Siplizumab

Start the discussion